GLP-1药物可能有助于对抗抗精神病药物引起的体重增加
GLP-1 Drugs May Help Combat Antipsychotic Weight Gain in Schizophrenia
一项系统综述和荟萃分析研究了GLP-1受体激动剂等药物在抗精神病药物治疗的精神分裂症患者中的减重效果,发现semaglutide和metformin等药物具有显著的减重效果,有助于改善患者的整体健康和生活质量。
研究团队通过网络荟萃分析,评估了多种药物在抗精神病药物治疗的精神分裂症患者中的减重效果,为临床提供了有效治疗方案。
— Meta-analysis ranks weight loss from drugs for antipsychotic-treated patients
November 2, 2026 • 4 min read
Antipsychotics have been a mainstay treatment for schizophrenia spectrum disorders for decades, but their metabolic side effects carry a significant treatment burden.
Life expectancy for individuals with serious mental illness, including schizophrenia, is roughly 10 to 25 years shorter than the general population, primarily due to weight gain and subsequent metabolic disease.
"Appropriate weight management in people with psychotic disorders is an important unmet need," said Jose Rubio, MD, of the Psychosis Center of Excellence at Northwell Zucker Hillside Hospital in Glen Oaks, New York. "Overweight is not an unavoidable price to pay for treating acute psychosis or preventing relapses."
Before weight-loss drugs like GLP-1 receptor agonists became available, many clinicians and patients viewed metabolic side effects as the inevitable price to pay for treating acute psychosis and preventing relapses, Rubio told MedPage Today.
These side effects also contribute to medication nonadherence, low self-esteem, decreased quality of life, and worse cognitive functioning, leading to significantly greater healthcare costs, noted Sri Mahavir Agarwal, MBBS, MD, PhD, of the University of Toronto Centre for Addiction and Mental Health, and colleagues in a systematic review and meta-analysis in JAMA Psychiatry.
"Thus, addressing the metabolic disturbances associated with antipsychotic use is necessary to improve the overall health and quality of life of individuals being treated with these medications," they emphasized.
Study Sheds Light on Effective Therapies
To find effective ways to tackle this burden, Agarwal's research team performed a network meta-analysis of 95 trials, identifying the treatments associated with the greatest weight loss in antipsychotic-treated patients with schizophrenia.
"This was the largest systematic review and meta-analysis of pharmacological interventions for reducing body weight in individuals with schizophrenia spectrum disorders treated with antipsychotics," Agarwal told MedPage Today.
The study examined 39 individual pharmacological interventions across 5,898 trial participants. Based on moderate-certainty evidence, the following drugs were associated with the largest, statistically significant mean reductions in body weight compared with placebo:
- Semaglutide (Wegovy): 10.98 kg (24.2 lb)
- Liraglutide (Saxenda): 5.43 kg (12.0 lb)
- Topiramate: 3.95 kg (8.7 lb)
- Metformin: 3.86 kg (8.5 lb)
- Exenatide (Byetta): 2.97 kg (6.5 lb)
Among these, semaglutide and metformin were observed to achieve a clinically meaningful weight loss of at least 5% of body weight. Beneficial effects on other metabolic outcomes, such as lipid and glucose levels, were also noted.
Other therapies, including ramelteon, nizatidine, and aripiprazole (Abilify), also demonstrated weight-reducing effects but were supported by very low-certainty evidence.
The findings build on prior network meta-analyses that have assessed pharmacological interventions to treat antipsychotic-associated weight gain.
"Metformin consistently had the most evidence for its effectiveness in this population, followed by moderate evidence for other interventions, such as topiramate, nizatidine, and sibutramine," Agarwal and team noted.
Prior reviews had included older GLP-1 agents, but the "field of neuroendocrinology has rapidly shifted in recent years, including introduction of newer GLP-1 receptor agonists like semaglutide, which are revolutionizing management of obesity and related comorbidities," they wrote.
Of note, the group's analysis did not include even newer therapies like tirzepatide (Zepbound). However, the authors emphasized that "there is potential for patients with schizophrenia spectrum disorders to benefit from ... emerging treatments across research and clinical contexts."
Tolerability and Prescribing
As expected, GLP-1 agents were associated with slightly higher rates of mild-to-moderate gastrointestinal (GI) side effects -- such as nausea, vomiting, diarrhea, and dyspepsia -- though discontinuation rates were not significantly higher compared with placebo.
Beyond well-established GI side effects to be cognizant of when starting GLP-1 drugs, Rubio noted that this drug class has been linked with fatigue, stomach paralysis, and inflammation of the pancreas.
"Pre-existing conditions need to be weighed in when making a decision about using these drugs, but for many people the risks are worth it given how much weight can be lost, the long-term consequences of overweight, and the relatively low risk of these complications, particularly the most severe," he said.
Barriers to Access Remain
Despite robust data supporting the efficacy of these therapies, access remains a major hurdle. Rubio pointed out that overcoming this barrier requires a fundamental paradigm shift.
"Now patients, families, and prescribers must change how they think about overweight in schizophrenia. They may need to 'denormalize' the association between psychotic disorders and overweight," he said. "As a field, we must emphasize that overweight is an avoidable driver of medical morbidity and premature mortality."
Insurance coverage restrictions continue to block patient access, emphasized Rubio. "We still see many patients for whom these drugs are not covered by their insurance," he said. "Regulations that assume explicitly that overweight is an avoidable driver of morbidity and premature mortality -- and therefore a quality target -- would facilitate more widespread coverage."
"We do not have paradigm changes every day in our field but certainly this is one of them, which is exciting," Rubio stated. "We must work to make sure that patients with psychosis, who may at times be in vulnerable positions, also benefit from this existing resource."
来源:MedPage Today · medpagetoday.com